Israel Englander Abb Vie Inc. Call Options Transaction History

Millennium Management LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$163.84 - $199.33 $54.5 Million - $66.3 Million	-332,500 Reduced 43.16%	437,900 $86.5 Million
Q2 2024 Aug 14, 2024	BUY	$154.79 - $180.76 $35.6 Million - $41.6 Million	230,300 Added 42.64%	770,400 $132 Million
Q1 2024 May 15, 2024	SELL	$159.82 - $182.1 $79.3 Million - $90.4 Million	-496,300 Reduced 47.89%	540,100 $98.4 Million
Q4 2023 Feb 14, 2024	BUY	$137.6 - $154.97 $11.9 Million - $13.4 Million	86,700 Added 9.13%	1,036,400 $161 Million
Q2 2023 Aug 14, 2023	SELL	$132.51 - $164.9 $31.9 Million - $39.7 Million	-240,800 Reduced 20.23%	949,700 $128 Million
Q1 2023 May 15, 2023	SELL	$144.61 - $166.54 $62.9 Million - $72.5 Million	-435,200 Reduced 26.77%	1,190,500 $190 Million
Q4 2022 Feb 14, 2023	BUY	$138.31 - $165.87 $91.9 Million - $110 Million	664,700 Added 69.17%	1,625,700 $263 Million
Q3 2022 Nov 14, 2022	BUY	$134.21 - $153.93 $29.2 Million - $33.5 Million	217,800 Added 29.31%	961,000 $129 Million

3,846

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $297B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.